Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05171647 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05171647 · ClinicalTrials.gov record · last posted 2026-08-05

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Study acronym: SUNMO
StatusActive, Not Recruiting
PhasePhase 3
Started2022-04-25
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed follicular lymphoma (trFL) and FL Grade 3B (FL3B) in comparison with a commonly used regimen in this participant population, rituximab, gemcitabine and oxaliplatin (R-GemOx).

Amendment record 48 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 48 times since 2021-12-20; most recent amendment 2026-05-05. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-09-06
Status change Recruiting→Active, Not Recruitingv37
2022-03-24
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT05171647
Lead Sponsor Hoffmann-La Roche
Conditions Non-Hodgkin Lymphoma
Enrollment 208 participants
Start Date 2022-04-25
Primary Completion 2025-02-17 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-08-05